N-{4-[2-(4-hydrazinocarbonylmethylphenyl)ethyl]-1,3-thiazol-2-yl}acetamide | 1030892-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{4-[2-(4-hydrazinocarbonylmethylphenyl)ethyl]-1,3-thiazol-2-yl}acetamide
• 英文别名: N-[4-[2-[4-(2-hydrazinyl-2-oxoethyl)phenyl]ethyl]-1,3-thiazol-2-yl]acetamide
• CAS: 1030892-01-3
• 化学式: C₁₅H₁₈N₄O₂S
• 分子量: 318.4
• InChiKey: PEDVJANTVUPHST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  {4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl}acetic acid 、 N,N'-羰基二咪唑 在 一水合肼 作用下， 以 N-甲基乙酰胺 、 水 为溶剂， 生成 N-{4-[2-(4-hydrazinocarbonylmethylphenyl)ethyl]-1,3-thiazol-2-yl}acetamide
  参考文献：
  名称：

  EP2172221

  摘要：

  公开号：

文献信息

• COMPOSITION FOR OPHTALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA
  申请人：Mashima Yukihiko

  公开号：US20100190834A1

  公开（公告）日：2010-07-29

  According to the present invention, a composition containing a VAP-1 inhibitor as an active ingredient, which is effective for ophthalmic diseases associated with hypoxia or ischemia can be provided. According to the present invention, moreover, an angiogenesis inhibitor that suppresses pathologic angiogenesis associated with hypoxia or ischemia can be provided.

  根据本发明，可以提供一种含有VAP-1抑制剂作为活性成分的组合物，该组合物对于与缺氧或缺血相关的眼科疾病具有有效性。此外，根据本发明，还可以提供一种抑制与缺氧或缺血相关的病理性血管生成的血管生成抑制剂。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CATARACT
  申请人：Mashima Yukihiko

  公开号：US20100210697A1

  公开（公告）日：2010-08-19

  The present invention aims to provide a pharmaceutical composition effective for the treatment of cataract. A pharmaceutical composition for the treatment of cataract, containing a VAP-1 inhibitor as an active ingredient, particularly a pharmaceutical composition for the treatment of cataract, containing a compound represented by the formula (I) and the like as an active ingredient: R 1 —NH—X—Y—Z  (I) wherein each symbol is as defined in the description.

  本发明旨在提供一种有效治疗白内障的药物组合物。一种用于治疗白内障的药物组合物，包含VAP-1抑制剂作为活性成分，特别是一种用于治疗白内障的药物组合物，包含化合物(I)式等作为活性成分：R1—NH—X—Y—Z  (I)，其中每个符号如描述中所定义。
• COMPOSITION FOR OPHTHALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA
  申请人：R-Tech Ueno, Ltd.

  公开号：EP2172221A1

  公开（公告）日：2010-04-07

  According to the present invention, a composition containing a VAP-1 inhibitor as an active ingredient, which is effective for ophthalmic diseases associated with hypoxia or ischemia can be provided. According to the present invention, moreover, an angiogenesis inhibitor that suppresses pathologic angiogenesis associated with hypoxia or ischemia can be provided.

  根据本发明，可以提供一种含有 VAP-1 抑制剂作为活性成分的组合物，该组合物对与缺氧或缺血相关的眼科疾病有效。此外，根据本发明，还可提供一种血管生成抑制剂，该抑制剂可抑制与缺氧或缺血相关的病理性血管生成。
• Composition for ophthalmic disease associated with hypoxia or ischemia
  申请人：R-Tech Ueno, Ltd.

  公开号：EP2599498A1

  公开（公告）日：2013-06-05

  According to the present invention, a composition containing a VAP-1 inhibitor as an active ingredient, which is effective for ophthalmic diseases associated with hypoxia or ischemia can be provided. According to the present invention, moreover, an angiogenesis inhibitor that suppresses pathologic angiogenesis associated with hypoxia or ischemia can be provided.

  根据本发明，可以提供一种含有 VAP-1 抑制剂作为活性成分的组合物，该组合物对与缺氧或缺血相关的眼科疾病有效。此外，根据本发明，还可提供一种血管生成抑制剂，该抑制剂可抑制与缺氧或缺血相关的病理性血管生成。
• EP2213303
  申请人：——

  公开号：——

  公开（公告）日：——